COVID-19 mRNA Vaccine and Myocarditis

Coronavirus disease 2019 (COVID-19) is believed to have originated in the Hua nan South China Seafood Market in Wuhan and can present with a spectrum of clinical manifestations. We report the case of 24-year-old male patient who developed chest pain after administration of the second dose of the Pfizer-BioNTech mRNA COVID-19 vaccine and who was diagnosed with myocarditis on work-up. LEARNING POINTS Localized injection site reactions and systemic adverse effects can occur after administration of the various COVID-19 vaccines. Healthcare providers should maintain a high index of suspicion regarding myocarditis after mRNA COVID-19 vaccination in the appropriate clinical scenario. Keywords: COVID-19, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, myocarditis, COVID-19 vaccine, side effects, adverse events, pericarditis, inflammation of the heart INTRODUCTION Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has resulted in a global health and economic crisis. Initially considered a respiratory tract disease, it is now known that it can cause multiple organ dysfunction and presents with a wide variety of complications (gastrointestinal, neurological, haematological, thromboembolic, immune and cardiovascular). Complications and outcomes may depend on disease severity and the comorbidities of the infected patient. For optimal management of these patients, understanding of the various systemic manifestations and complications of SARS-CoV-2 is essential. Vaccination against SARS-CoV-2 infection is considered a valid approach for controlling the pandemic.